12:22 pm Furiex Pharmaceuticals confirms Takeda’s submission of an NDA for trelagliptin succinate (SYR-472) in Japan for the treatment of type 2 diabetes
View todays social media effects on FURX
View the latest stocks trending across Twitter. Click to view dashboard
See who Furiex is hiring next, click here to view
